1. Academic Validation
  2. Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome

Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome

  • Sci Adv. 2024 Feb 2;10(5):eadj7813. doi: 10.1126/sciadv.adj7813.
Wei Wang 1 Jinyou Li 2 Siyuan Cui 3 Jiayu Li 1 Xianlong Ye 4 Zhe Wang 1 Tingting Zhang 1 Xuan Jiang 1 Yulin Kong 1 Xin Chen 3 Yong Q Chen 1 Shenglong Zhu 1 3
Affiliations

Affiliations

  • 1 Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China.
  • 2 Affiliated Hospital of Jiangnan University, Wuxi 214122, China.
  • 3 Jiangnan University Medical Center, Wuxi 214002, China.
  • 4 Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China.
Abstract

Metabolic syndrome (MetS) is closely associated with an increased risk of dementia and cognitive impairment, and a complex interaction of genetic and environmental dietary factors may be implicated. Free Fatty Acid Receptor 4 (Ffar4) may bridge the genetic and dietary aspects of MetS development. However, the role of Ffar4 in MetS-related cognitive dysfunction is unclear. In this study, we found that Ffar4 expression is down-regulated in MetS mice and MetS patients with cognitive impairment. Conventional and microglial conditional knockout of Ffar4 exacerbated high-fat diet (HFD)-induced cognitive dysfunction and anxiety, whereas microglial Ffar4 overexpression improved HFD-induced cognitive dysfunction and anxiety. Mechanistically, we found that microglial Ffar4 regulated microglial activation through type I interferon signaling. Microglial depletion and NF-κB inhibition partially reversed cognitive dysfunction and anxiety in microglia-specific Ffar4 knockout MetS mice. Together, these findings uncover a previously unappreciated role of Ffar4 in negatively regulating the NF-κB-IFN-β signaling and provide an attractive therapeutic target for delaying MetS-associated cognitive decline.

Figures
Products
Inhibitors & Agonists
Other Products